1. Vert, M. (1985) Polyvalent polymeric drug carriers, In S.D. Bruck (ed.), Critical Reviews in Therapeutic Drug Carrier Systems, CRC Press Inc., Florida, 2(3), pp. 291–327.
2. Tomlinson, E. (1986) (Patho)physiology and the temporal and spatial aspects of drug delivery, In E. Tomlinson and S.S. Davis (eds.), Site-Specific Drug Delivery, Cell Biology, Medical and Pharmaceutical Aspects, John Wiley &Sons Ltd., 1–26.
3. Ehrlich, P. (1906) Collected Study on Immunology, John Wiley & Sons,New York, 11, 442.
4. Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Hofstead, S., Casazza, A.M., Firestone, R.A., Hellstrom, I. and Hellstrom, K.E. (1993) Cure of xenografted human carcinomas by BR96-Doxorubicin immunoconjugates, Science 261, 212–215.
5. Uckun, F.M., Evans, W.E., Forsyth, C.J., Waddick, K.G., Ahlgren, L.T., Chelstrom, L.M., Burkhardt, A., Bolen, J. and Myer, D.E. (1995) Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases, Science 267, 886–891.